
  
    
      
        Background_NNP
        Reversible_NNP protein_NN phosphorylation_NN is_VBZ gaining_VBG
        recognition_NN as_IN a_DT potentially_RB important_JJ mechanism_NN of_IN
        post-translational_JJ regulation_NN in_IN protozoan_NN parasites_NNS ,_,
        especially_RB those_DT belonging_VBG to_TO the_DT 
        Apicomplexan_NNP family_NN ._. The_DT
        dephosphorylation_NN of_IN phosphoproteins_NNS is_VBZ universally_RB
        catalyzed_JJ by_IN protein_NN phosphatases_NNS that_WDT are_VBP classified_VBN into_IN
        two_CD major_JJ functional_JJ groups_NNS ,_, protein_NN tyrosine_NN phosphatase_NN
        (_( PTP_NNP )_) and_CC protein_NN serine_NN /_NN threonine_NN phosphatase_NN (_( PP_NNP )_)
        although_IN enzymes_NNS with_IN various_JJ degrees_NNS of_IN dual-specificity_JJ
        are_VBP also_RB encountered_VBN [_NN 1_CD 2_CD 3_CD 4_CD 5_CD ]_NN ._. The_DT majority_NN of_IN
        Ser_NNP /_NN Thr_NNP phosphatases_NNS belong_VBP to_TO three_CD classical_JJ groups_NNS ,_,
        namely_RB PP_NNP 1_CD ,_, PP_NNP 2_CD A_DT ,_, and_CC PP_NNP 2_CD B_NNP (_( calcineurin_NN )_) ,_, and_CC possess_VBP
        similar_JJ primary_JJ structures_NNS in_IN their_PRP$ catalytic_JJ cores_NNS [_NN 2_CD 3_CD 6_CD
        ]_NN ._. PP_NNP 1_CD ,_, in_IN particular_JJ ,_, exhibits_VBZ an_DT extremely_RB high_JJ degree_NN
        of_IN sequence_NN conservation_NN through_IN evolution_NN ,_, and_CC its_PRP$
        orthologs_NNS and_CC isoforms_NNS are_VBP found_VBN in_IN all_DT eukaryotic_JJ cells_NNS [_NN
        6_CD 7_CD ]_NN ._. In_IN various_JJ organisms_NNS ,_, PP_NNP 1_CD regulates_VBZ such_JJ diverse_JJ
        cellular_JJ processes_NNS as_IN cell_NN cycle_NN progression_NN ,_, protein_NN
        synthesis_NN ,_, carbohydrate_NN metabolism_NN ,_, transcription_NN ,_, and_CC
        neuronal_NN signaling_VBG [_NN 3_CD 7_CD ]_NN ,_, underscoring_VBG its_PRP$ profound_JJ
        importance_NN in_IN biology_NN ._. The_DT PP_NNP 1_CD and_CC PP_NNP 2_CD A_DT phosphatases_NNS are_VBP
        differentially_RB affected_VBN by_IN natural_JJ toxins_NNS such_JJ as_IN okadaic_JJ
        acid_NN (_( OA_NNP )_) and_CC microcystin-_NN LR_NNP ._. For_IN example_NN ,_, the_DT
        characteristic_JJ IC_NNP 
        50_CD values_NNS for_IN OA_NNP fall_NN in_IN the_DT range_NN :_:
        PP_NNP 2_CD A_DT ,_, 1_CD -_: 5_CD nM_NN ,_, PP_NNP 1_CD ,_, 20_CD -_: 80_CD nM_NN ,_, whereas_IN PP_NNP 2_CD B_NNP is_VBZ highly_RB
        resistant_JJ to_TO both_DT [_NN 2_CD 3_CD 7_CD ]_NN ._. In_IN contrast_NN ,_, tautomycin_NN
        affects_VBZ PP_NNP 1_CD and_CC PP_NNP 2_CD A_DT nearly_RB equally_RB ,_, but_CC fails_VBZ to_TO inhibit_VB
        other_JJ phosphatases_NNS [_NN 8_CD ]_NN ._.
        In_IN the_DT past_JJ few_JJ years_NNS ,_, a_DT number_NN of_IN phosphatase_NN
        activities_NNS and_CC putative_JJ sequences_NNS have_VBP been_VBN reported_VBN in_IN 
        P_NN ._. falciparum_NN [_NN 9_CD ]_NN ._. These_DT include_VBP a_DT
        PP_NNP 2_CD A_DT [_NN 10_CD ]_NN ,_, a_DT PP_NNP 2_CD B-_NNP like_IN activity_NN [_NN 10_CD ]_NN ,_, a_DT unique_JJ
        chimeric_JJ PP_NNP 2_CD C_NNP [_NN 11_CD ]_NN ,_, two_CD putative_JJ sexual-stage_JJ
        phosphatases_NNS -_: PPα_NNP [_NN 12_CD ]_NN and_CC PPβ_NNP [_NN 13_CD ]_NN ,_, and_CC a_DT
        tetratricopeptide_NN repeat-containing_JJ phosphatase_NN ,_, PP_NNP 5_CD [_NN 14_CD ]_NN
        ._. Preliminary_JJ studies_NNS revealed_VBD the_DT presence_NN of_IN a_DT protein_NN
        phosphatase_NN activity_NN in_IN crude_NN extracts_NNS of_IN RBC-grown_NNP 
        P_NN ._. falciparum_NN that_WDT exhibited_VBN
        toxin-sensitivity_JJ resembling_VBG that_IN of_IN PP_NNP 1_CD [_NN 15_CD ]_NN ._.
        Uninfected_NNP RBC_NNP ,_, in_IN contrast_NN ,_, possessed_VBD mainly_RB a_DT PP_NNP 2_CD A-_NNP like_IN
        activity_NN ._. Because_IN of_IN its_PRP$ potential_JJ importance_NN in_IN a_DT variety_NN
        of_IN signalling_VBG pathways_NNS of_IN the_DT parasite_NN ,_, we_PRP have_VBP turned_VBN our_PRP$
        attention_NN to_TO defining_VBG the_DT PP_NNP 1_CD phosphatase_NN and_CC its_PRP$
        regulation_NN in_IN 
        P_NN ._. falciparum_NN ._.
        In_IN this_DT communication_NN ,_, we_PRP report_VBP the_DT exact_JJ sequence_NN of_IN a_DT
        PP_NNP 1_CD cDNA_NN in_IN 
        P_NN ._. falciparum_NN ,_, the_DT corresponding_JJ
        gene_NN sequence_NN in_IN 
        P_NN ._. falciparum_NN chromosome_NN 14_CD ,_, the_DT
        enzymatic_JJ properties_NNS of_IN the_DT recombinant_JJ enzyme_NN ,_, and_CC its_PRP$
        inhibition_NN by_IN mammalian_JJ physiological_JJ PP_NNP 1_CD -_: inhibitors_NNS ,_,
        namely_RB ,_, inhibitor-_NN 1_CD (_( I-_NNP 1_LS )_) and_CC inhibitor-_NN 2_CD (_( I-_NNP 2_LS )_) ._.
        Post-transcriptional_NNP gene_NN silencing_VBG using_VBG synthetic_JJ short_JJ
        interfering_VBG RNA_NNP (_( siRNA_NN )_) molecules_NNS has_VBZ been_VBN recently_RB used_VBN to_TO
        ablate_NN specific_JJ mRNAs_NNS and_CC thus_RB ,_, produce_VB phenotypic_JJ
        mutations_NNS in_IN specific_JJ genes_NNS [_NN 16_CD 17_CD ]_NN ._. We_PRP have_VBP adopted_VBN
        this_DT technology_NN to_TO knockdown_NN specific_JJ gene_NN products_NNS in_IN RNA_NNP
        viruses_NNS that_WDT are_VBP obligatory_JJ intracellular_NN parasites_NNS [_NN 18_CD ]_NN
        ._. In_IN the_DT present_JJ study_NN ,_, we_PRP have_VBP successfully_RB used_VBN a_DT similar_JJ
        strategy_NN to_TO generate_VB phenotypic_JJ PP_NNP 1_CD -_: deficient_NN 
        P_NN ._. falciparum_NN parasites_NNS ._.
      
      
        Results_NNS and_CC Discussion_NNP
        
          Identification_NNP of_IN the_DT PfPP_NNP 1_CD cDNA_NN sequence_NN
          Various_JJ pairs_NNS of_IN oligodeoxynucleotide_NN primers_NNS were_VBD
          designed_VBN on_IN the_DT basis_NN of_IN the_DT PlasmoDB-predicted_NNP mRNA_NN
          sequence_NN (_( Gene_NNP chr_NN 14_CD __NN 1_CD ._. phat_NN __NN 133_CD )_) ,_, and_CC employed_VBN in_IN reverse_NN
          transcription-_NN PCR_NNP (_( RT-PCR_NNP )_) amplification_NN using_VBG Pf_NNP 3_CD D_NNP 7_CD
          total_JJ mRNA_NN as_IN template_NN ._. Based_VBN on_IN the_DT prediction_NN ,_, primers_NNS
          5_CD '_POS ATGGCATTAGAAATAGATATAGATAATG_NNP 3_CD '_POS (_( primer_NN A_DT in_IN Fig_NNP ._. 1_LS ,_, the_DT
          start_NN codon_NN in_IN bold_JJ )_) and_CC 5_CD '_POS TTATTTCCGACAAAAAGAAATATATGG_NNP
          3_CD '_POS were_VBD first_RB tested_VBN ,_, but_CC no_DT product_NN was_VBD obtained_VBN ._. Since_IN
          there_EX was_VBD no_DT other_JJ ATG_NNP within_IN a_DT reasonable_JJ distance_NN
          upstream_RB that_WDT was_VBD in_IN the_DT same_JJ reading_NN frame_NN ,_, we_PRP proceeded_VBD
          on_IN the_DT assumption_NN that_IN the_DT 3_CD '_POS -_: end_NN of_IN the_DT mRNA_NN might_MD be_VB
          different_JJ ._. Thus_RB ,_, the_DT second_JJ primer_NN was_VBD replaced_VBN by_IN a_DT
          series_NN of_IN nested_JJ primers_NNS (_( based_VBN on_IN the_DT genomic_JJ sequence_NN )_) ,_,
          each_DT of_IN which_WDT was_VBD paired_VBN with_IN primer_NN A_DT in_IN RT-PCR_NNP ._. The_DT
          combination_NN of_IN primer_NN A_DT and_CC the_DT primer_NN
          5_CD '_POS TTTTTTAATTTGCTGCTTTCTTTTTTTCC_NNP 3_CD '_POS (_( Fig_NNP ._. 1_LS )_) eventually_RB
          produced_VBD a_DT RT-PCR_NNP product_NN that_WDT was_VBD cloned_VBN into_IN pGEM-T_JJ
          vector_NN and_CC sequenced_JJ ._. The_DT cDNA_NN sequence_NN contained_VBD a_DT
          915_CD -_: nucleotide_NN long_JJ open_JJ reading_NN frame_NN corresponding_JJ to_TO a_DT
          polypeptide_NN 304_CD amino_JJ acid_NN in_IN length_NN and_CC ending_VBG with_IN a_DT
          TAA_NNP stop_NN codon_NN ._.
          Comparison_NNP of_IN the_DT cDNA_NN sequence_NN with_IN the_DT genomic_JJ
          sequence_NN (_( in_IN Chromosome_NNP 14_CD at_IN TIGR_NNP )_) revealed_VBD that_IN the_DT
          coding_VBG sequence_NN is_VBZ divided_VBN into_IN five_CD exons_NNS ,_, of_IN which_WDT the_DT
          first_JJ two_CD are_VBP the_DT largest_JJS and_CC contain_VB most_JJS of_IN the_DT
          catalytic_JJ core_NN of_IN the_DT phosphatase_NN (_( Fig_NNP ._. 1_LS and_CC 2_LS )_) ._. The_DT
          intron_NN sequences_NNS are_VBP pronouncedly_RB more_JJR AT-rich_NNP than_IN
          exons_NNS ,_, and_CC contained_VBD homopolymeric_JJ repeats_NNS ,_, a_DT feature_NN
          which_WDT ,_, in_IN our_PRP$ experience_NN ,_, is_VBZ common_JJ in_IN 
          Plasmodium_NNP genes_NNS ._.
          BLAST_NN analysis_NN of_IN the_DT predicted_VBN primary_JJ structure_NN of_IN
          the_DT protein_NN revealed_VBD its_PRP$ clear_JJ identity_NN with_IN the_DT PP_NNP 1_CD
          class_NN (_( Fig_NNP ._. 2_LS )_) ._. It_PRP is_VBZ to_TO be_VB mentioned_VBN that_IN among_IN all_PDT the_DT
          Ser_NNP /_NN Thr_NNP phosphatases_NNS ,_, PP_NNP 1_CD has_VBZ been_VBN subjected_VBN to_TO the_DT most_RBS
          extensive_JJ structure-function_JJ analysis_NN [_NN 19_CD 20_CD 21_CD 22_CD 23_CD 24_CD
          25_CD 26_CD ]_NN ._. In_IN fact_NN ,_, it_PRP was_VBD one_CD of_IN the_DT first_JJ phosphatases_NNS
          for_IN which_WDT the_DT three-dimensional_JJ structure_NN was_VBD solved_VBN [_NN 26_CD
          27_CD ]_NN ._. A_DT representative_NN alignment_NN in_IN Fig_NNP ._. 2_LS demonstrates_VBZ
          the_DT high_JJ sequence_NN conservation_NN between_IN the_DT human_JJ and_CC 
          Plasmodium_NNP PP_NNP 1_CD sequences_NNS ._. The_DT
          catalytic_JJ core_NN of_IN all_DT members_NNS of_IN the_DT PP_NNP 1_CD and_CC PP_NNP 2_CD families_NNS
          are_VBP very_RB conserved_JJ ,_, and_CC roughly_RB corresponds_NNS to_TO residues_NNS
          5_CD -_: 260_CD of_IN PfPP_NNP 1_CD (_( Fig_NNP ._. 2_LS )_) ._. This_DT region_NN contains_VBZ all_PDT the_DT
          signature_NN motifs_NNS and_CC conserved_JJ residues_NNS that_WDT have_VBP been_VBN
          shown_VBN to_TO be_VB important_JJ for_IN the_DT fundamental_JJ steps_NNS of_IN
          catalysis_NNS ,_, including_VBG substrate_NN binding_JJ ,_, metal_NN ion_NN
          coordination_NN ,_, and_CC interaction_NN with_IN the_DT phosphate_NN group_NN [_NN
          19_CD 26_CD 27_CD 28_CD ]_NN ._. It_PRP is_VBZ to_TO be_VB noted_VBN that_IN at_IN 304_CD amino_JJ acid_NN
          residues_NNS ,_, PfPP_NNP 1_CD is_VBZ the_DT shortest_JJS PP_NNP 1_CD known_VBN to_TO date_NN ,_, and_CC
          lacks_VBZ a_DT short_JJ proline-rich_JJ stretch_NN at_IN the_DT C-_NNP terminal_NN end_NN
          (_( Fig_NNP ._. 2_LS )_) ._.
        
        
          Expression_NNP and_CC catalytic_JJ properties_NNS of_IN PfPP_NNP 1_CD
          In_IN order_NN to_TO characterize_VB the_DT PfPP_NNP 1_CD cDNA_NN we_PRP subcloned_JJ
          it_PRP into_IN pET-_NN 15_CD b_SYM such_JJ that_IN the_DT protein_NN is_VBZ expressed_VBN with_IN
          an_DT N-_NNP terminal_NN (_( His_PRP$ )_) 
          6_CD -_: tag_NN ._. As_IN shown_VBN in_IN Fig_NNP ._. 3_LS ,_, a_DT protein_NN
          band_NN of_IN approximately_RB 37_CD ,_, 000_CD Mr_NNP was_VBD produced_VBN from_IN the_DT
          pET-_NN 15_CD b-_NN PfPP_NNP 1_CD clone_NN ,_, which_WDT is_VBZ in_IN agreement_NN with_IN the_DT
          predicted_VBN molecular_JJ weight_NN of_IN 34_CD ,_, 904_CD of_IN PfPP_NNP 1_CD and_CC roughly_RB
          another_DT 2_CD ,_, 000_CD added_VBD for_IN the_DT (_( His_PRP$ )_) 
          6_CD region_NN of_IN pET-_NN 15_CD b_SYM (_( Novagen_NNP :_: Madison_NNP ,_,
          WI_NNP )_) ._. The_DT protein_NN specifically_RB reacted_VBD with_IN a_DT monoclonal_NN
          anti-_NN His_PRP$ antibody_NN and_CC also_RB with_IN a_DT polyclonal_NN antibody_NN
          against_IN full-length_JJ human_JJ PP_NNP 1_CD (_( Transduction_NNP Laboratories_NNPS :_:
          Lexington_NNP ,_, KY_NNP )_) ._. The_DT recombinant_JJ protein_NN was_VBD purified_JJ
          through_IN nickel-chelation_JJ chromatography_NN and_CC tested_VBN for_IN
          phosphatase_NN activity_NN ._. It_PRP dephosphorylated_JJ the_DT small_JJ
          substrate_NN 
          p_NN NPP_NNP ,_, as_RB well_RB as_IN histone_NN ,_, labelled_JJ
          at_IN Ser_NNP residues_NNS ._. Interestingly_RB ,_, it_PRP also_RB showed_VBD decent_JJ
          activity_NN on_IN a_DT Tyr-phosphorylated_NNP synthetic_JJ peptide_NN ._. The_DT V_NNP
          
          max_NN values_NNS (_( μmol_NN Pi_NNP liberated_VBD /_NN mg_NN
          enzyme_NN /_NN min_NN )_) against_IN these_DT three_CD substrates_NNS (_( pNPP_NN ,_,
          phosphoserine-histone_JJ ,_, phosphotyrosine_NN peptide_NN )_) were_VBD ,_,
          respectively_RB :_: 12_CD +_NN 2_CD ,_, 8_CD +_NN 1_CD ,_, and_CC 2_CD +_NN 0_CD ._. 5_LS ._. An_DT equivalent_NN
          protein_NN fraction_NN ,_, obtained_VBN from_IN 
          E_NNP ._. coli_NNS containing_VBG vector_NN alone_RB
          (_( without_IN insert_NN )_) ,_, showed_VBD no_DT activity_NN against_IN any_DT of_IN these_DT
          substrates_NNS ._. It_PRP has_VBZ been_VBN recently_RB shown_VBN that_DT rabbit_NN PP_NNP 1_CD ,_,
          expressed_VBD in_IN 
          E_NNP ._. coli_NNS ,_, also_RB possessed_VBD Tyr_NNP
          phosphatase_NN activity_NN ._. In_IN contrast_NN ,_, native_JJ PP_NNP 1_CD isolated_VBN
          from_IN rabbit_NN muscle_NN or_CC expressed_VBD in_IN Sf_NNP 9_CD insect_NN cells_NNS
          contained_VBD only_RB Ser_NNP /_NN Thr_NNP phosphatase_NN activity_NN but_CC no_DT Tyr_NNP
          phosphatase_NN activity_NN [_NN 24_CD ]_NN ._. It_PRP was_VBD concluded_VBN that_IN this_DT
          apparent_JJ difference_NN might_MD be_VB due_JJ to_TO subtle_JJ changes_NNS in_IN
          protein_NN folding_VBG in_IN eukaryotic_JJ versus_CC prokaryotic_JJ cellular_JJ
          environments_NNS ._. It_PRP remains_VBZ to_TO be_VB seen_VBN whether_IN this_DT is_VBZ a_DT
          general_JJ feature_NN of_IN all_DT PP_NNP 1_CD ._.
          To_TO obtain_VB biochemical_JJ evidence_NN for_IN the_DT identity_NN of_IN the_DT
          recombinant_JJ PfPP_NNP 1_CD ,_, we_PRP tested_VBD the_DT effect_NN of_IN specific_JJ
          phosphatase_NN inhibitors_NNS and_CC selected_VBN mutations_NNS on_IN the_DT
          phosphatase_NN activity_NN ._. Mutation_NNP of_IN Asn_NNP 122_CD to_TO Asp_NNP by_IN
          site-directed_JJ mutagenesis_NNS destroyed_VBD the_DT phosphatase_NN
          activity_NN ,_, confirming_VBG the_DT essential_JJ role_NN of_IN this_DT residue_NN
          of_IN PP_NNP 1_CD in_IN catalysis_NNS [_NN 19_CD ]_NN ._. PfPP_NNP 1_CD was_VBD inhibited_VBD by_IN NaF_NNP ,_,
          inorganic_JJ orthophosphate_NN ,_, and_CC pyrophosphate_NN at_IN respective_JJ
          IC_NNP 
          50_CD values_NNS of_IN 2_CD ._. 5_CD mM_NN ,_, 10_CD mM_NN ,_, and_CC 90_CD μM_NN
          (_( data_NNS not_RB shown_VBN )_) ._. Similar_JJ values_NNS were_VBD recently_RB obtained_VBN
          for_IN 
          Arabidopsis_NNP PP_NNP 1_CD [_NN 8_CD ]_NN ._. PfPP_NNP 1_CD was_VBD
          also_RB inhibited_VBD by_IN tautomycin_NN ,_, I-_NNP 1_CD ,_, I-_NNP 2_CD ,_, and_CC OA_NNP with_IN IC_NNP 
          50_CD values_NNS of_IN 0_CD ._. 8_CD ,_, 400_CD ,_, 7_CD ,_, and_CC 100_CD nM_NN ,_,
          respectively_RB (_( Fig_NNP ._. 4_LS )_) ._. These_DT values_NNS are_VBP comparable_JJ to_TO
          those_DT obtained_VBN with_IN various_JJ PP_NNP 1_CD isoforms_NNS recombinantly_RB
          expressed_VBD in_IN 
          E_NNP ._. coli_NNS [_NN 25_CD 29_CD ]_NN ._. The_DT sensitivity_NN
          of_IN PfPP_NNP 1_CD to_TO these_DT natural_JJ toxins_NNS is_VBZ consistent_JJ with_IN the_DT
          fact_NN that_IN the_DT loop_NN sequence_NN between_IN the_DT β_NN 12_CD and_CC β_NN 13_CD
          regions_NNS plays_VBZ a_DT direct_JJ role_NN in_IN binding_VBG these_DT toxins_NNS [_NN 23_CD
          26_CD ]_NN ,_, and_CC this_DT sequence_NN is_VBZ entirely_RB conserved_JJ in_IN PfPP_NNP 1_CD
          (_( Fig_NNP ._. 2_LS )_) ._. Recently_RB ,_, a_DT few_JJ additional_JJ residues_NNS that_WDT are_VBP
          closer_JJR to_TO the_DT N-_NNP terminus_JJ in_IN the_DT PP_NNP 1_CD sequence_NN have_VBP also_RB
          been_VBN shown_VBN to_TO be_VB important_JJ in_IN the_DT interaction_NN with_IN I-_NNP 2_CD [_NN
          24_CD ]_NN ;_: in_IN PfPP_NNP 1_CD numbers_NNS ,_, these_DT residues_NNS are_VBP :_: E_NNP 52_CD ,_, E_NNP 54_CD ,_,
          and_CC D_NNP 164_CD ,_, E_NNP 165_CD ,_, K_NNP 166_CD (_( Fig_NNP ._. 2_LS )_) ._. In_IN yeast_NN PP_NNP 1_CD (_( Glc_NNP 7_CD p_NN )_) ,_, the_DT
          double_JJ mutant_JJ E_NNP 52_CD A_DT /_NN E_NNP 54_CD A_DT and_CC the_DT triple_JJ mutant_JJ
          D_NNP 164_CD A_DT /_NN E_NNP 165_CD A_DT /_NN K_NNP 166_CD A_DT showed_VBD IC_NNP 
          50_CD values_NNS for_IN I-_NNP 2_CD that_WDT were_VBD
          respectively_RB 8_CD and_CC 300_CD times_NNS the_DT wild_JJ type_NN enzyme_NN values_NNS
          [_NN 24_CD ]_NN ._. As_IN shown_VBN in_IN Fig_NNP ._. 4_LS ,_, a_DT similar_JJ loss_NN of_IN inhibition_NN
          by_IN I-_NNP 2_CD was_VBD also_RB observed_VBN when_WRB the_DT corresponding_JJ mutations_NNS
          were_VBD introduced_VBN into_IN PfPP_NNP 1_CD ,_, although_IN they_PRP did_VBD not_RB affect_VB
          the_DT catalytic_JJ activity_NN (_( specific_JJ activity_NN )_) (_( data_NNS not_RB
          shown_VBN )_) ._. Together_RB ,_, these_DT results_NNS provide_VBP experimental_JJ
          confirmation_NN of_IN the_DT catalytic_JJ identity_NN of_IN PfPP_NNP 1_CD ._.
        
        
          Expression_NNP of_IN native_JJ PfPP_NNP 1_CD
          As_IN mentioned_VBN earlier_RBR ,_, inhibition_NN studies_NNS using_VBG OA_NNP and_CC
          calyculin_NN A_DT suggested_VBD the_DT existence_NN of_IN a_DT PP_NNP 1_CD -_: like_IN
          activity_NN in_IN 
          P_NN ._. falciparum_NN extracts_NNS [_NN 15_CD ]_NN ._.
          However_RB ,_, our_PRP$ attempts_NNS to_TO purify_NN the_DT native_JJ PfPP_NNP 1_CD enzyme_NN
          by_IN chromatographic_JJ procedures_NNS resulted_VBD in_IN only_RB small_JJ
          amounts_NNS of_IN activity_NN ,_, probably_RB due_JJ to_TO rapid_JJ inactivation_NN
          during_IN fractionation_NN ._. To_TO determine_VB if_IN PfPP_NNP 1_CD is_VBZ expressed_VBN
          in_IN 
          Plasmodium_NNP ,_, we_PRP have_VBP ,_, therefore_RB ,_,
          taken_VBN an_DT immunological_JJ approach_NN ._. First_LS ,_, cell-free_JJ
          extracts_NNS of_IN different_JJ erythrocytic_JJ stages_NNS of_IN 
          P_NN ._. falciparum_NN were_VBD subjected_VBN to_TO
          Western_JJ blot_NN using_VBG a_DT monoclonal_NN antibody_NN that_WDT was_VBD raised_VBN
          against_IN nearly_RB full-length_JJ human_JJ PP_NNP 1_CD and_CC showed_VBD a_DT broad_JJ
          species_NNS specificity_NN (_( see_VB Materials_NNPS and_CC Methods_NNP )_) ._. As_IN shown_VBN
          in_IN Fig_NNP ._. 5_LS A_DT ,_, a_DT major_JJ band_NN of_IN the_DT expected_VBN size_NN of_IN 35_CD k_NN was_VBD
          observed_VBN in_IN all_DT stages_NNS including_VBG gametes_NNS ._. A_DT peptide_NN
          antibody_NN ,_, specific_JJ for_IN human_JJ PP_NNP 1_CD (_( Materials_NNPS and_CC Methods_NNP )_) ,_,
          did_VBD not_RB detect_VB the_DT band_NN ._. The_DT gametogenesis_NNS was_VBD confirmed_VBN
          by_IN the_DT appearance_NN of_IN Pfg_NNP 27_CD ,_, an_DT early_JJ gamete-specific_JJ
          protein_NN [_NN 30_CD ]_NN ._. Having_VBG demonstrated_VBN that_IN the_DT monoclonal_NN
          antibody_NN was_VBD specific_JJ for_IN PP_NNP 1_CD ,_, we_PRP used_VBD it_PRP in_IN an_DT attempt_NN
          to_TO inhibit_VB PfPP_NNP 1_CD activity_NN 
          in_IN vitro_NN ._. At_IN optimal_NN
          concentrations_NNS ,_, the_DT antibody_NN almost_RB completely_RB inhibited_VBD
          (_( 90_CD %_NN inhibition_NN )_) recombinant_JJ PfPP_NNP 1_CD (_( including_VBG its_PRP$ Tyr_NNP
          phosphatase_NN activity_NN )_) ,_, and_CC also_RB inhibited_VBD the_DT phosphatase_NN
          activity_NN of_IN the_DT 
          P_NN ._. falciparum_NN extract_NN by_IN about_IN 70_CD %_NN
          (_( data_NNS not_RB shown_VBN )_) ._. Under_IN the_DT same_JJ conditions_NNS ,_, the_DT
          human-specific_JJ antibody_NN had_VBD no_DT effect_NN ._. Finally_RB ,_, it_PRP has_VBZ
          been_VBN shown_VBN that_IN affinity_NN resins_NNS containing_VBG immobilized_JJ
          microcystin_NN specifically_RB bind_NN toxin-sensitive_JJ
          phosphatases_NNS such_JJ as_IN PP_NNP 1_CD and_CC PP_NNP 2_CD A_DT [_NN 31_CD ]_NN ._. Thus_RB ,_, we_PRP
          passed_VBD soluble_JJ cytosolic_JJ Pf_NNP extract_VB through_IN
          microcystin-_NN Sepharose_NNP ,_, and_CC the_DT bound_VBN proteins_NNS were_VBD
          analyzed_VBN on_IN SDS-PAGE_NNP followed_VBN by_IN immunoblot_NN using_VBG the_DT
          anti-_NN PP_NNP 1_CD antibody_NN ._. The_DT blot_NN revealed_VBD that_IN the_DT 35_CD kDa_NN
          PfPP_NNP 1_CD polypeptide_NN indeed_RB specifically_RB bound_VBN to_TO
          microcystin_NN (_( Fig_NNP ._. 5_LS B_NNP )_) ,_, correlating_VBG the_DT antigenic_JJ
          reactivity_NN of_IN PfPP_NNP 1_CD with_IN its_PRP$ affinity_NN for_IN the_DT toxin_NN ._.
          Pre-incubation_NNP of_IN the_DT extract_NN with_IN microcystin_NN
          specifically_RB prevented_VBD binding_JJ of_IN PfPP_NNP 1_CD to_TO the_DT
          column_NN ._.
        
        
          Generation_NNP of_IN phenotypic_JJ PfPP_NNP 1_CD mutants_NNS by_IN PTGS_NNP
          using_VBG RNAi_NNP
          RNA_NNP interference_NN (_( RNAi_NNP )_) ,_, mediated_JJ by_IN short_JJ interfering_VBG
          double-stranded_JJ RNA_NNP molecules_NNS (_( siRNA_NN or_CC dsRNA_NN )_) ,_, is_VBZ now_RB
          recognized_VBN as_IN a_DT major_JJ mechanism_NN of_IN post-transcriptional_JJ
          gene_NN silencing_VBG (_( PTGS_NNP )_) in_IN essentially_RB all_DT eukaryotes_NNS [_NN 16_CD
          ]_NN ._. Recently_RB ,_, the_DT technique_NN has_VBZ been_VBN successfully_RB applied_VBN
          to_TO cultured_JJ mammalian_JJ cells_NNS ,_, whereby_WRB introduction_NN of_IN
          21_CD -_: nucleotide_NN long_JJ synthetic_JJ dsRNA_NN molecules_NNS
          corresponding_JJ to_TO specific_JJ mRNA_NN sequences_NNS effectively_RB and_CC
          specifically_RB degraded_JJ the_DT cognate_NN mRNAs_NNS and_CC abrogated_JJ the_DT
          expression_NN of_IN the_DT corresponding_JJ proteins_NNS [_NN 17_CD 18_CD ]_NN ._. This_DT
          prompted_VBD us_PRP to_TO test_VB a_DT similar_JJ approach_NN to_TO knockdown_NN PfPP_NNP 1_CD
          function_NN in_IN the_DT erythrocytic_JJ 
          P_NN ._. falciparum_NN stages_NNS ._. Our_PRP$ initial_JJ
          attempts_NNS with_IN standardized_JJ transfection_NN procedures_NNS using_VBG
          OligofectAMINE_NNP (_( Life_NNP Technologies_NNPS :_: Bethesda_NNP ,_, MD_NNP )_) with_IN the_DT
          dsRNA_NN did_VBD not_RB produce_VB an_DT appreciable_JJ loss_NN of_IN PfPP_NNP 1_CD ._. We_PRP
          then_RB resorted_JJ to_TO the_DT electroporation_NN procedure_NN originally_RB
          developed_VBD for_IN DNA_NNP transfection_NN in_IN 
          Plasmodium_NNP by_IN Wellems_NNP and_CC
          co-workers_NNS [_NN 32_CD ]_NN ,_, as_IN detailed_JJ under_IN Materials_NNPS and_CC
          Methods_NNP ._. A_DT representative_NN set_NN of_IN results_NNS shown_VBN in_IN Fig_NNP ._.
          6_CD clearly_RB demonstrates_VBZ loss_NN of_IN PfPP_NNP 1_CD by_IN the_DT RNAi_NNP
          procedure_NN ,_, while_IN the_DT control_JJ PP_NNP 2_CD A_DT was_VBD not_RB significantly_RB
          affected_VBN ._. Loss_NN of_IN PfPP_NNP 1_CD resulted_VBD in_IN concomitant_NN
          inhibition_NN of_IN parasite_NN growth_NN as_IN evidenced_VBN by_IN the_DT drastic_JJ
          reduction_NN in_IN 3_CD H-_NNP hypoxanthine_NN incorporation_NN ._. These_DT results_NNS
          suggest_VBP that_IN PfPP_NNP 1_CD plays_VBZ an_DT essential_JJ role_NN in_IN 
          Plasmodium_NNP replication_NN ._. The_DT facts_NNS
          that_IN the_DT parasite_NN culture_NN was_VBD asynchronous_JJ ,_, i_NNP ._. e_SYM ._. ,_,
          contained_VBD all_DT three_CD major_JJ stages_NNS (_( ring_NN ,_, trophozoite_NN ,_, and_CC
          schizont_NN )_) (_( data_NNS not_RB shown_VBN )_) and_CC that_IN the_DT effect_NN of_IN dsRNA_NN
          was_VBD severe_JJ ,_, suggest_VBP that_IN PfPP_NNP 1_CD is_VBZ required_VBN for_IN cell_NN cycle_NN
          progression_NN at_IN all_DT stages_NNS of_IN the_DT parasite_NN ._. This_DT is_VBZ
          further_RBR supported_VBN by_IN the_DT expression_NN of_IN PP_NNP 1_CD protein_NN in_IN all_PDT
          the_DT parasitic_JJ stages_NNS (_( Fig_NNP ._. 5_LS )_) ._. Taken_VBN together_RB ,_, this_DT is_VBZ
          consistent_JJ with_IN the_DT established_VBN role_NN of_IN PP_NNP 1_CD in_IN eukaryotic_JJ
          DNA_NNP synthesis_NN and_CC cell_NN cycle_NN progression_NN ,_, as_IN discussed_VBN
          below_IN ._.
          PP_NNP 1_CD is_VBZ one_CD of_IN the_DT major_JJ protein_NN phosphatases_NNS found_VBD in_IN
          all_DT eukaryotic_JJ cells_NNS ._. The_DT activity_NN of_IN the_DT catalytic_JJ
          subunit_NN of_IN PP_NNP 1_CD is_VBZ controlled_VBN by_IN its_PRP$ interaction_NN with_IN a_DT
          large_JJ number_NN of_IN regulatory_JJ subunits_NNS ,_, many_JJ of_IN which_WDT also_RB
          target_NN it_PRP to_TO specific_JJ subcellular_NN compartments_NNS [_NN 7_CD 24_CD 33_CD
          ]_NN ._. The_DT major_JJ ones_NNS include_VBP the_DT glycogen-targeting_JJ
          subunits_NNS (_( G_NNP 
          M_NNP ,_, G_NNP 
          L_NNP )_) [_NN 34_CD ]_NN ,_, myofibrillar-targeting_JJ
          subunit_NN (_( M_NNP 
          110_CD )_) [_NN 34_CD ]_NN ,_, nuclear_JJ inhibitor_NN of_IN
          PP_NNP 1_CD (_( NIPP-_NNP 1_LS )_) [_NN 35_CD ]_NN ,_, PP_NNP 1_CD nuclear_JJ targeting_VBG subunit_NN
          (_( PNUTS_NNP )_) [_NN 36_CD 37_CD ]_NN ,_, mitosis-regulating_JJ subunit_NN Sds_NNP 22_CD [_NN 38_CD
          39_CD 40_CD ]_NN ,_, ribosomal_JJ protein_NN L_NNP 5_CD [_NN 41_CD ]_NN and_CC small_JJ cytosolic_JJ
          inhibitory_NN proteins_NNS ,_, I-_NNP 1_CD ,_, I-_NNP 2_CD ,_, and_CC DARRP-_NNP 32_CD (_( Dopamine_NNP and_CC
          cAMP-regulated_JJ phosphoprotein_NN ,_, Mr_NNP 32_CD ,_, 000_CD )_) [_NN 7_CD 23_CD 25_CD ]_NN ._.
          The_DT physiological_JJ role_NN of_IN many_JJ of_IN these_DT interactions_NNS has_VBZ
          been_VBN revealed_VBN in_IN recent_JJ studies_NNS ._. A_DT temperature-sensitive_JJ
          mutant_JJ of_IN the_DT yeast_NN PP_NNP 1_CD (_( Glc_NNP 7_CD )_) ,_, for_IN example_NN ,_, exhibits_VBZ a_DT
          block_NN in_IN the_DT M_NNP phase_NN of_IN the_DT cell_NN division_NN cycle_NN ,_, and_CC
          elevated_VBD expression_NN of_IN Sds_NNP 22_CD suppresses_NNS this_DT defect_NN [_NN 38_CD
          ]_NN ._. Structure-function_NNP analysis_NN of_IN recombinant_JJ mammalian_JJ
          PP_NNP 1_CD has_VBZ recently_RB begun_VBN to_TO map_VB specific_JJ residues_NNS involved_VBN
          in_IN interaction_NN with_IN other_JJ molecules_NNS ._. Interestingly_RB ,_, all_PDT
          these_DT residues_NNS are_VBP conserved_JJ in_IN PfPP_NNP 1_CD ,_, and_CC a_DT few_JJ examples_NNS
          are_VBP presented_VBN here_RB ._. Co-crystal_NNP structure_NN of_IN PP_NNP 1_CD and_CC a_DT G_NNP 
          M_NNP peptide_NN [_NN 42_CD ]_NN ,_, as_RB well_RB as_IN
          mutagenesis_NNS studies_NNS [_NN 43_CD ]_NN of_IN the_DT yeast_NN PP_NNP 1_CD ortholog_NN ,_,
          Glc_NNP 7_CD ,_, have_VBP demonstrated_VBN a_DT role_NN of_IN specific_JJ PP_NNP 1_CD residues_NNS
          in_IN PP_NNP 1_CD -_: G_NNP 
          M_NNP interaction_NN ._. In_IN the_DT PfPP_NNP 1_CD sequence_NN ,_,
          these_DT residues_NNS are_VBP :_: I_PRP 167_CD ,_, L_NNP 241_CD ,_, F_NN 255_CD ,_, L_NNP 264_CD ,_, C_NNP 289_CD ,_, and_CC
          F_NN 291_CD (_( Fig_NNP ._. 2_LS )_) ._. As_IN mentioned_VBN ,_, the_DT β_NN 12_CD -_: loop-β_JJ 13_CD region_NN ,_,
          important_JJ in_IN interaction_NN with_IN natural_JJ toxins_NNS [_NN 23_CD ]_NN ,_, is_VBZ
          fully_RB conserved_JJ in_IN PfPP_NNP 1_CD (_( Fig_NNP ._. 2_LS )_) ._. Two_CD residues_NNS ,_, recently_RB
          shown_VBN to_TO be_VB important_JJ for_IN interaction_NN with_IN DARPP-_NNP 32_CD [_NN 22_CD
          ]_NN ,_, are_VBP also_RB conserved_JJ in_IN PfPP_NNP 1_CD ;_: these_DT are_VBP :_: Met_NNP 288_CD and_CC
          Cys_NNP 289_CD (_( Fig_NNP ._. 2_LS )_) ._. We_PRP have_VBP provided_VBN experimental_JJ evidence_NN
          of_IN an_DT important_JJ role_NN of_IN a_DT number_NN of_IN invariant_NN residues_NNS of_IN
          PfPP_NNP 1_CD in_IN the_DT interaction_NN with_IN I-_NNP 2_CD (_( Fig_NNP ._. 2_LS and_CC 4_LS )_) ._. Based_VBN on_IN
          such_JJ overwhelming_JJ conservation_NN of_IN functionally_RB important_JJ
          residues_NNS ,_, we_PRP propose_VBP that_IN orthologs_NNS of_IN many_JJ of_IN these_DT
          PP_NNP 1_CD -_: interacting_VBG proteins_NNS may_MD also_RB exist_VB in_IN 
          Plasmodium_NNP and_CC function_NN in_IN similar_JJ
          roles_NNS ._. The_DT use_NN of_IN recombinant_JJ PfPP_NNP 1_CD and_CC protein-protein_JJ
          interaction_NN techniques_NNS should_MD aid_VB in_IN characterizing_VBG these_DT
          physiological_JJ regulatory_JJ subunits_NNS of_IN PfPP_NNP 1_CD ._. Our_PRP$ ability_NN
          to_TO generate_VB PP_NNP 1_CD -_: deficient_NN 
          P_NN ._. falciparum_NN parasites_NNS will_MD allow_VB
          us_PRP to_TO study_VB the_DT "_'' mutant_JJ "_'' phenotype_NN in_IN further_JJ detail_NN and_CC
          understand_VB the_DT role_NN of_IN this_DT highly_RB conserved_JJ phosphatase_NN
          in_IN malarial_NN biochemistry_NN and_CC pathophysiology_NN ._. These_DT
          studies_NNS are_VBP in_IN progress_NN ._.
          As_IN mentioned_VBN earlier_RBR ,_, Li_NNP and_CC Baker_NNP [_NN 12_CD ]_NN described_VBD a_DT
          putative_JJ phosphatase_NN DNA_NNP sequence_NN in_IN 
          Plasmodium_NNP ,_, the_DT mRNA_NN of_IN which_WDT was_VBD
          detected_VBN in_IN the_DT sexual_JJ stages_NNS of_IN the_DT parasite_NN ._. The_DT
          predicted_VBN protein_NN ,_, named_VBD PPα_NNP ,_, was_VBD 889_CD amino_JJ acid_NN long_JJ ,_,
          and_CC contained_VBD a_DT unique_JJ N-_NNP terminal_NN extension_NN of_IN about_IN 500_CD
          amino_JJ acids_NNS ._. The_DT C-_NNP terminal_NN 345_CD amino_JJ acids_NNS ,_, containing_VBG
          the_DT putative_JJ catalytic_JJ domain_NN ,_, had_VBD 5_CD unique_JJ peptide_NN
          stretches_VBZ that_WDT were_VBD called_VBN "_'' inserts_NNS "_'' ._. When_WRB these_DT inserts_NNS
          were_VBD omitted_VBN from_IN the_DT alignment_NN ,_, the_DT rest_NN of_IN the_DT sequence_NN
          showed_VBD significant_JJ similarity_NN with_IN PP_NNP 1_CD phosphatases_NNS [_NN 12_CD
          ]_NN ._. Clearly_RB ,_, further_JJ studies_NNS are_VBP needed_VBN to_TO identify_VB the_DT
          PPα_NNP protein_NN and_CC characterize_VB its_PRP$ potentially_RB interesting_JJ
          identity_NN ._.
          While_IN our_PRP$ manuscript_NN was_VBD being_VBG written_VBN ,_, McRobert_NNP and_CC
          McConkey_NNP [_NN 44_CD ]_NN achieved_VBD similar_JJ success_NN in_IN using_VBG the_DT
          RNAi_NNP strategy_NN to_TO ablate_NN dihydroorotate_NN dehydrogenase_NN
          (_( DHODH_NNP )_) of_IN 
          P_NN ._. falciparum_NN ._. Although_IN the_DT
          protein_NN level_NN was_VBD not_RB directly_RB monitored_VBN ,_, the_DT loss_NN of_IN
          DHODH_NNP mRNA_NN was_VBD confirmed_VBN by_IN RT-PCR_NNP ._. This_DT resulted_VBD in_IN
          inhibition_NN of_IN parasite_NN growth_NN ,_, consistent_JJ with_IN the_DT role_NN
          of_IN DHODH_NNP in_IN pyrimidine_NN biosynthesis_NNS ,_, essential_JJ for_IN
          parasite_NN DNA_NNP replication_NN ._. These_DT authors_NNS introduced_VBD the_DT
          double-stranded_JJ RNA_NNP by_IN electroporation_NN also_RB ,_, using_VBG
          conditions_NNS very_RB similar_JJ to_TO ours_PRP ._. Thus_RB ,_, although_IN the_DT exact_JJ
          mechanism_NN of_IN the_DT RNA_NNP uptake_NN remains_VBZ to_TO be_VB elucidated_JJ ,_, the_DT
          electroporation_NN procedure_NN must_MD have_VB allowed_VBN the_DT dsRNA_NN to_TO
          traverse_NN the_DT various_JJ erythrocytic_JJ and_CC parasitic_JJ membranes_NNS
          to_TO enter_VB the_DT parasitic_JJ cells_NNS ._.
          The_DT success_NN in_IN ablating_VBG PfPP_NNP 1_CD is_VBZ particularly_RB
          gratifying_VBG to_TO us_PRP on_IN a_DT number_NN of_IN accounts_NNS ._. As_IN mentioned_VBN ,_,
          PP_NNP 1_CD is_VBZ a_DT highly_RB conserved_JJ enzyme_NN ,_, and_CC toxin-sensitive_JJ
          Ser_NNP /_NN Thr_NNP phosphatase_NN activities_NNS are_VBP also_RB found_VBN in_IN
          erythrocytes_NNS [_NN 15_CD ]_NN ._. Thus_RB ,_, use_NN of_IN PP_NNP 1_CD inhibitors_NNS ,_, such_JJ
          as_IN okadaic_JJ acid_NN or_CC tautomycin_NN (_( Fig_NNP ._. 4_LS )_) would_MD affect_VB the_DT
          parasite_NN as_RB well_RB as_IN the_DT host_NN ,_, making_VBG conclusions_NNS
          difficult_JJ ._. The_DT dsRNA_NN ,_, in_IN contrast_NN ,_, is_VBZ known_VBN to_TO be_VB
          extremely_RB specific_JJ for_IN its_PRP$ intended_VBN target_NN ,_, such_JJ that_IN a_DT
          single_JJ nucleotide_NN mismatch_NN prevents_VBZ its_PRP$ action_NN [_NN 17_CD ]_NN ._.
          This_DT has_VBZ allowed_VBN us_PRP to_TO create_VB specific_JJ phenotypic_JJ loss_NN of_IN
          PfPP_NNP 1_CD ._. Moreover_RB ,_, RNAi_NNP will_MD permit_VB the_DT ablation_NN of_IN
          essential_JJ gene_NN products_NNS ,_, at_IN any_DT time_NN point_NN in_IN infection_NN ,_,
          or_CC on_IN a_DT desired_VBN parasitic_JJ stage_NN following_VBG
          synchronization_NN ._. Lastly_NNP ,_, traditional_JJ genetic_JJ manipulation_NN
          in_IN eukaryotes_NNS ,_, including_VBG the_DT 
          Apicomplexa_NNP ,_, is_VBZ a_DT relatively_RB
          difficult_JJ and_CC elaborate_VB procedure_NN [_NN 45_CD 46_CD ]_NN ._. Thus_RB ,_, we_PRP
          believe_VBP that_IN the_DT RNAi_NNP strategy_NN will_MD become_VB a_DT powerful_JJ and_CC
          convenient_JJ tool_NN in_IN 
          Plasmodium_NNP functional_JJ genomics_NNS ,_,
          particularly_RB in_IN the_DT studies_NNS of_IN phylogenetically_RB conserved_JJ
          signalling_VBG molecules_NNS ._.
        
      
      
        Conclusion_NNP
        
        P_NN ._. falciparum_NN contains_VBZ a_DT PP_NNP 1_CD protein_NN
        phosphatase_NN that_WDT is_VBZ virtually_RB identical_JJ to_TO its_PRP$ orthologs_NNS in_IN
        other_JJ species_NNS in_IN both_DT sequence_NN and_CC biochemical_JJ properties_NNS ._.
        Based_VBN on_IN the_DT established_VBN physiological_JJ role_NN of_IN PP_NNP 1_CD in_IN other_JJ
        organisms_NNS such_JJ as_IN mammals_NNS and_CC yeast_NN ,_, PfPP_NNP 1_CD may_MD regulate_VB a_DT
        variety_NN of_IN parasitic_JJ pathways_NNS ,_, including_VBG glycogen_NN
        metabolism_NN ,_, glucose_NN repression_NN ,_, and_CC cell_NN cycle_NN progression_NN ._.
        Indeed_RB ,_, the_DT successful_JJ use_NN of_IN RNA_NNP interference_NN to_TO ablate_NN
        PfPP_NNP 1_CD confirms_VBZ its_PRP$ essential_JJ role_NN on_IN parasitic_JJ growth_NN ._. The_DT
        catalytic_JJ subunit_NN of_IN PfPP_NNP 1_CD is_VBZ expressed_VBN in_IN all_PDT the_DT
        erythrocytic_JJ stages_NNS of_IN the_DT parasite_NN and_CC is_VBZ specifically_RB
        inhibited_VBD by_IN mammalian_JJ physiological_JJ inhibitors_NNS ,_,
        inhibitor-_NN 1_CD and_CC inhibitor-_NN 2_CD ._. Thus_RB ,_, an_DT in-depth_JJ study_NN of_IN
        PfPP_NNP 1_CD and_CC its_PRP$ interacting_VBG subunits_NNS may_MD shed_VB light_JJ on_IN the_DT
        regulation_NN of_IN the_DT relevant_JJ pathways_NNS in_IN this_DT clinically_RB
        important_JJ family_NN of_IN parasites_NNS ._.
      
      
        Materials_NNS and_CC methods_NNS
        
          Materials_NNS
          Histone_NNP and_CC the_DT catalytic_JJ subunit_NN of_IN PKA_NNP were_VBD
          purchased_VBN from_IN Sigma_NNP (_( St_NNP ._. Louis_NNP ,_, MO_NNP )_) ,_, and_CC rabbit_NN I-_NNP 2_CD ,_, the_DT
          
          v-abl_JJ protein_NN tyrosine_NN kinase_NN ,_, and_CC
          its_PRP$ peptide_NN substrate_NN EAIYAAPFAKKK_NNP were_VBD from_IN New_NNP England_NNP
          Biolabs_NNP (_( Bedford_NNP ,_, MA_NNP )_) ._. Okadaic_NNP acid_NN (_( OA_NNP )_) and_CC recombinant_JJ
          I-_NNP 1_CD [_NN 22_CD ]_NN were_VBD kind_NN gifts_NNS from_IN R_NN ._. Honkanen_NNP and_CC S_NNP ._.
          Shenolikar_NNP (_( Duke_NNP University_NNP )_) ,_, respectively_RB ._. The_DT
          monoclonal_NN anti-_NN PP_NNP 1_CD antibody_NN was_VBD raised_VBN against_IN a_DT 25_CD ._. 6_CD
          kDa_NN fragment_NN of_IN human_JJ PP_NNP 1_CD α_NN (_( residue_NN 5_CD -_: 226_CD )_) ,_, and_CC was_VBD
          purchased_VBN from_IN Transduction_NNP Laboratories_NNPS (_( Lexington_NNP ,_, KY_NNP )_) ._.
          This_DT antibody_NN reacts_VBZ with_IN all_DT mammalian_JJ and_CC avian_NN PP_NNP 1_CD
          tested_VBN ,_, but_CC does_VBZ not_RB react_VB with_IN other_JJ PP_NNP classes_NNS ._. The_DT
          other_JJ PP_NNP 1_CD antibody_NN (_( a_DT kind_NN gift_NN from_IN R_NN ._. Honkanen_NNP )_) was_VBD
          specific_JJ for_IN human_JJ PP_NNP 1_CD ,_, and_CC was_VBD raised_VBN in_IN rabbit_NN against_IN
          a_DT synthetic_JJ peptide_NN corresponding_JJ to_TO the_DT last_JJ 13_CD residues_NNS
          of_IN human_JJ PP_NNP 1_CD (_( PITPPRNSAKAKK_NNP ;_: Fig_NNP ._. 2_LS )_) ._. The_DT anti-_NN PfPP_NNP 2_CD A_DT
          antibody_NN was_VBD raised_VBN in_IN rabbit_NN against_IN the_DT peptide_NN
          MLIFKDTPDSRNSIKN_NNP ,_, corresponding_JJ to_TO residue_NN 285_CD -_: 300_CD of_IN the_DT
          previously_RB described_VBN PfPP_NNP 2_CD A_DT [_NN 10_CD ]_NN ._. The_DT RIG_NNP plasmid_NN was_VBD
          kindly_RB provided_VBN by_IN W_NNP ._. Hol_NNP (_( University_NNP of_IN Washington_NNP ,_,
          Howard_NNP Hughes_NNP Medical_NNP Institute_NNP )_) [_NN 47_CD ]_NN ._. Monoclonal_NNP
          antibody_NN against_IN the_DT early_JJ sexual-stage_JJ 
          P_NN ._. falciparum_NN antigen_NN Pfg_NNP 27_CD [_NN 30_CD ]_NN
          was_VBD a_DT generous_JJ gift_NN from_IN N_NNP ._. Kumar_NNP (_( Johns_NNP Hopkins_NNP
          University_NNP ,_, Baltimore_NNP ,_, MD_NNP )_) ._. Microcystin-coupled_NNP sepharose_NN
          was_VBD purchased_VBN from_IN Upstate_NNP Biotechnology_NNP ,_, Inc_NNP ._. (_( Lake_NNP
          Placid_NNP ,_, NY_NNP )_) ._.
        
        
          Amplification_NNP ,_, cloning_VBG ,_, and_CC mutagenesis_NNS of_IN PfPP_NNP 1_CD
          cDNA_NN
          Total_NNP RNA_NNP was_VBD isolated_VBN from_IN asynchronous_JJ 
          P_NN ._. falciparum_NN 3_CD D_NNP 7_CD cells_NNS grown_VBN in_IN
          human_JJ A-_NNP positive_JJ erythrocytes_NNS essentially_RB as_IN before_IN [_NN 48_CD
          49_CD ]_NN ._. Various_JJ pairs_NNS of_IN primers_NNS were_VBD designed_VBN on_IN the_DT
          basis_NN of_IN the_DT relevant_JJ sequences_NNS of_IN chromosome_NN 14_CD ._. T_NN 
          m_NN values_NNS of_IN the_DT primers_NNS were_VBD in_IN the_DT
          range_NN of_IN 65_CD -_: 72_CD °_NN C_NNP in_IN order_NN to_TO achieve_VB high_JJ specificity_NN in_IN
          reverse_NN transcription_NN (_( RT_NNP )_) as_RB well_RB as_IN PCR_NNP ._. RT_NNP reaction_NN
          was_VBD carried_VBN out_RB at_IN 60_CD °_NN C_NNP for_IN 1_CD ._. 5_CD hrs_NNS using_VBG the_DT C_NNP ._. therm_NN ._.
          polymerase_NN kit_NN (_( Roche_NNP Molecular_NNP Biochemicals_NNP ,_, Cat_NNP ._. No_UH ._.
          2016311_CD )_) ._. The_DT RT_NNP reaction_NN was_VBD incorporated_VBN into_IN PCR_NNP ,_,
          carried_VBD out_IN using_VBG a_DT mixture_NN of_IN Taq_NNP (_( Roche_NNP )_) and_CC Pfu_NNP
          (_( Stratagene_NNP )_) polymerases_NNS (_( 20_CD :_: 1_LS )_) to_TO ensure_VB high_JJ fidelity_NN [_NN
          50_CD ]_NN ._. Elongation_NNP in_IN PCR_NNP was_VBD performed_VBN at_IN 62_CD °_NN C_NNP ._. The_DT
          various_JJ products_NNS were_VBD gel-purified_JJ and_CC cloned_VBN in_IN pGEM-T_JJ
          by_IN "_'' TA_NNP cloning_VBG "_'' (_( Promega_NNP ,_, WI_NNP )_) ._. The_DT clones_NNS were_VBD initially_RB
          screened_VBD by_IN restriction_NN analysis_NN and_CC finally_RB confirmed_VBN by_IN
          sequencing_VBG ._.
          All_DT site-directed_JJ mutagenesis_NNS were_VBD performed_VBN using_VBG the_DT
          megaprimer_NN procedure_NN [_NN 51_CD ]_NN ,_, and_CC the_DT mutations_NNS were_VBD
          confirmed_VBN by_IN sequencing_VBG ._. DNA_NNP sequencing_VBG was_VBD carried_VBN out_IN
          by_IN cycle_NN sequencing_VBG using_VBG the_DT PRISM_NNP Big_NNP Dye_NNP Terminator_NNP
          sequencing_VBG kit_NN and_CC AmpliTaq_NNP DNA_NNP polymerase_NN (_( Perkin-_NNP Elmer_NNP ,_,
          Division_NNP of_IN PE_NNP /_NN ABI_NNP )_) ._.
        
        
          Expression_NNP and_CC assay_NN of_IN recombinant_JJ PfPP_NNP 1_CD
          phosphatase_NN
          Growth_NN and_CC induction_NN of_IN 
          E_NNP ._. coli_NNS BL_NNP 21_CD (_( DE_NNP 3_LS )_) containing_VBG
          pET-_NN 15_CD b-_NN PfPP_NNP 1_CD and_CC the_DT RIG_NNP plasmid_NN were_VBD carried_VBN out_IN using_VBG
          procedures_NNS described_VBD earlier_JJR [_NN 14_CD 48_CD ]_NN ,_, except_IN that_IN the_DT
          culture_NN was_VBD grown_VBN at_IN 18_CD °_NN C_NNP in_IN the_DT presence_NN of_IN 2_CD mM_NN MnCl_NNP 
          2_CD ,_, and_CC IPTG_NNP concentration_NN was_VBD lowered_VBN
          to_TO 0_CD ._. 4_CD mM_NN ._. The_DT (_( His_PRP$ )_) 
          6_CD -_: tagged_VBN PfPP_NNP 1_CD expressed_VBD from_IN
          pET-_NN 15_CD b-_NN PfPP_NNP 1_CD was_VBD purified_JJ through_IN Ni_NNP +_NN 2_CD -_: chelation_NN
          chromatography_NN [_NN 14_CD ]_NN as_IN described_VBN by_IN the_DT manufacturer_NN
          (_( Novagen_NNP )_) ,_, with_IN 1_CD mM_NN MnCl_NNP 
          2_CD being_VBG present_JJ in_IN all_PDT the_DT buffers_NNS ._.
          The_DT imidazole-eluted_JJ His-tagged_NNP PfPP_NNP 1_CD was_VBD dialyzed_JJ
          against_IN 50_CD mM_NN Tris-_NNP Cl_NNP (_( pH_NN 7_CD ._. 5_LS )_) ,_, 100_CD mM_NN NaCl_NNP ,_, 25_CD %_NN
          glycerol_NN ,_, 1_CD mM_NN DTT_NNP (_( buffer_NN A_DT )_) ,_, and_CC stored_VBD in_IN small_JJ
          portions_NNS at_IN -_: 80_CD °_NN C_NNP ._.
          Phosphatase_NNP activities_NNS were_VBD assayed_JJ essentially_RB as_IN
          described_VBN [_NN 14_CD 19_CD 52_CD ]_NN ._. Unless_IN otherwise_RB mentioned_VBN ,_, 80_CD
          μl_NN reactions_NNS contained_VBD 2_CD mM_NN of_IN MnCl_NNP 
          2_CD and_CC requisite_JJ amount_NN of_IN recombinant_JJ
          enzyme_NN in_IN buffer_NN A_DT ._. Where_WRB mentioned_VBN ,_, OA_NNP was_VBD directly_RB
          added_VBN to_TO the_DT reaction_NN ._. When_WRB I-_NNP 2_CD was_VBD used_VBN ,_, it_PRP was_VBD
          pre-incubated_JJ with_IN PfPP_NNP 1_CD at_IN 32_CD °_NN C_NNP for_IN 30_CD min_NN ._. I-_NNP 1_CD was_VBD
          prephosphorylated_JJ by_IN PKA_NNP in_IN a_DT standard_JJ kinase_NN reaction_NN
          containing_VBG 200_CD μM_NN γ-thiophosphorylated_JJ ATP_NNP ._. 32_CD P-_NNP labelled_JJ
          histone_NN was_VBD prepared_VBN by_IN phosphorylation_NN with_IN PKA_NNP in_IN the_DT
          presence_NN of_IN γ-_NN 32_CD P_NN [_NN ATP_NNP ]_NN essentially_RB as_IN described_VBN ,_,
          followed_VBN by_IN removal_NN of_IN the_DT free_JJ ATP_NNP by_IN gel_NN filtration_NN [_NN
          19_CD 52_CD ]_NN ._. The_DT resultant_JJ phosphohistone_NN is_VBZ exclusively_RB
          phosphorylated_JJ at_IN Ser_NNP residues_NNS [_NN 53_CD ]_NN ._. 32_CD P-_NNP labeled_VBD
          peptide_NN EAI_NNP (_( Yp_NNP )_) AAPFAKKK_NNP ,_, phosphorylated_JJ at_IN the_DT single_JJ Tyr_NNP
          residue_NN by_IN pp_NN 43_CD v-ablkinase_JJ ,_, was_VBD prepared_VBN essentially_RB as_IN
          described_VBN [_NN 19_CD 52_CD ]_NN ._. Phosphatase_NNP reactions_NNS were_VBD
          initiated_VBN by_IN the_DT addition_NN of_IN the_DT substrate_NN ._. The_DT liberated_VBD
          32_CD P_NN was_VBD quantitated_JJ by_IN a_DT phosphomolybdate_NN extraction_NN
          assay_NN as_IN described_VBN previously_RB [_NN 14_CD ]_NN ._. Reactions_NNP were_VBD
          followed_VBN with_IN time_NN ,_, and_CC results_NNS were_VBD corrected_VBN by_IN
          subtraction_NN of_IN the_DT corresponding_JJ values_NNS from_IN an_DT
          enzyme-free_JJ reaction_NN ._.
        
        
          Analysis_NNP of_IN native_JJ PfPP_NNP 1_CD
          
          P_NN ._. falciparum_NN 3_CD D_NNP 7_CD was_VBD grown_VBN on_IN
          A-_NNP positive_JJ human_JJ erythrocytes_NNS in_IN the_DT presence_NN of_IN
          homologous_RB serum_NN as_IN described_VBN earlier_JJR [_NN 48_CD 49_CD ]_NN ._. When_WRB
          needed_VBN ,_, cultures_NNS were_VBD synchronized_VBN in_IN two_CD steps_NNS [_NN 49_CD 54_CD ]_NN
          :_: (_( i_NNP )_) schizonts_NNS were_VBD purified_JJ by_IN flottation_NN over_IN 65_CD %_NN
          (_( v_NN /_NN v_NN )_) Percoll_NNP (_( Pharmacia_NNP )_) followed_VBN by_IN incubation_NN with_IN
          fresh_JJ erythrocytes_NNS (_( 5_CD %_NN haematocrit_NN )_) ;_: (_( ii_NN )_) the_DT cultures_NNS
          were_VBD then_RB left_VBN to_TO mature_VB into_IN rings_NNS and_CC treated_VBN with_IN 5_CD %_NN
          D-_NNP sorbitol_NN for_IN 15_CD min_NN at_IN 37_CD °_NN C_NNP ._. The_DT purity_NN of_IN individual_JJ
          stages_NNS was_VBD greater_JJR than_IN 95_CD %_NN as_IN confirmed_VBN by_IN microscopic_JJ
          observation_NN of_IN a_DT stained_JJ thin_JJ smear_NN of_IN the_DT culture_NN ._.
          Sexual_NNP stage_NN parasite_NN was_VBD generated_VBN as_IN described_VBN [_NN 30_CD ]_NN
          ._.
        
        
          Transfection_NNP by_IN inhibitory_NN dsRNA_NN
          The_DT following_JJ 21_CD -_: mer_NN RNA_NNP molecules_NNS ,_, corresponding_JJ to_TO
          the_DT underlined_VBD sequence_NN in_IN Fig_NNP ._. 1_LS ,_, were_VBD synthesized_JJ as_IN
          described_VBN [_NN 18_CD ]_NN and_CC deprotected_JJ according_VBG to_TO the_DT
          manufacturer_NN 's_POS protocol_NN (_( Dharmacon_NNP Research_NNP ,_, Lafayette_NNP ,_,
          CO_NNP )_) :_:
          Sense_NN :_: (_( 5_CD '_POS )_) GAGGUAACCACGAAUGCGCdTdT_NNP (_( 3_CD '_'' )_)
          Antisense_NNP :_: (_( 5_CD '_POS )_) GCGCAUUCGUGGUUACCUCdTdT_NNP (_( 3_CD '_'' )_)
          The_DT negative_JJ control_NN luciferase_NN RNA_NNP was_VBD the_DT same_JJ as_IN
          the_DT double-stranded_JJ GL_NNP 3_CD RNA_NNP described_VBD previously_RB [_NN 17_CD ]_NN ._.
          The_DT RNAs_NNP were_VBD annealed_JJ 
          in_IN vitro_NN to_TO form_VB double-stranded_JJ
          RNA_NNP (_( dsRNA_NN )_) [_NN 18_CD ]_NN and_CC electroporation_NN was_VBD carried_VBN out_IN
          essentially_RB as_IN described_VBN [_NN 32_CD ]_NN ._. In_IN brief_JJ ,_, 3_CD μg_NN dsRNA_NN in_IN
          800_CD μl_NN of_IN incomplete_JJ cytomix_NN [_NN 32_CD ]_NN was_VBD added_VBN to_TO infected_JJ
          RBC_NNP (_( at_IN 10_CD -_: 15_CD %_NN parasitemia_NN )_) ,_, and_CC electroporation_NN was_VBD
          performed_VBN using_VBG a_DT Bio-_NNP Rad_NNP Gene_NNP Pulsar_NNP unit_NN at_IN settings_NNS of_IN
          200_CD Ω_NN ,_, 2_CD kV_NN ,_, and_CC 25_CD μF_NN ._. Control_NN cells_NNS were_VBD identically_RB
          electroporated_JJ without_IN RNA_NNP ._. The_DT cells_NNS were_VBD then_RB grown_VBN in_IN
          12_CD -_: well_RB plates_NNS in_IN triplicate_NN wells_NNS ,_, and_CC measurement_NN of_IN
          3_CD H-_NNP hypoxanthine_NN incorporation_NN was_VBD carried_VBN out_RB at_IN 24_CD hr_NN
          post-electroporation_JJ using_VBG standard_JJ procedures_NNS [_NN 49_CD ]_NN ,_,
          except_IN that_DT parasites_NNS were_VBD liberated_VBD with_IN saponin_NN ,_,
          pelleted_JJ ,_, and_CC counts_VBZ in_IN the_DT pellet_NN measured_VBD following_VBG
          solubilization_NN ._. Parasites_NNP from_IN unlabelled_JJ but_CC otherwise_RB
          identical_JJ cultures_NNS were_VBD analyzed_VBN in_IN Western_JJ blot_NN using_VBG a_DT
          mixture_NN of_IN anti-_NN PP_NNP 1_CD and_CC anti-_NN PfPP_NNP 2_CD A_DT antibodies_NNS (_( see_VB
          Materials_NNPS and_CC Methods_NNP )_) ._.
        
      
    
  
